Y-mAbs Therapeutics to Present at PEGS Boston 14 February 2019
NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)... Read more
NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)... Read more
MinervaX, a privately held Danish biotech company, announces today that is has been awarded an in... Read more
This free ELIXIR Innovation and SME Forum with a focus on Genomics and Associated Data in Nationa... Read more
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical... Read more
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical... Read more
NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Proceeds to fund Phase 2/3 trial of inhaled TD139 in idiopathic pulmonary fibrosis (IPF) and advancement... Read more
The Nordic countries have launched an ambitious plan to fast-track the development of a sustainable bioeconomy... Read more
NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more